Friday, 15 Dec 2017

You are here

The RheumNow Week in Review - 26 May 2017

Dr. Jack Cush Reviews highlights from the past week on RheumNow.com:

  1. Study of 24 erosive RA pts shows addition of anabolic teriparatide did not significantly reduce the rate/volume of erosions http://buff.ly/2rh1hsO
  2. Swedish study 27k+ AS, PsA and uSpA are at increased risk for Acute Coronary syndrome & stroke events https://t.co/Zq49quPo3T
  3. β-Defensin2 is a biomarker reflects IL-17A-driven skin dz in psoriasis, not PsA. Highly correlates w/ PASI & IL-17A https://t.co/JmCmMIN0Cq  Study of 8 pts controls the expression of 170 proteins in blood, nonlesional skin, and lesional skin
  4. Tight control (TC) trial in PsA (TiCOPA) shows that TC is twice costly & QALYs- not cost-effective in most analyses https://t.co/MxFR1wjl8N
  5. Claims data on 2495 JIA pts shows significantly more serious bacterial infx w/ TNFi use (HR 2.72) compared to DMARDs https://t.co/CKu9oIOzlj
  6. Among 323 ANCA-Assoc Vasculitis pts, CTX Rx(SIR 3.1) had 4.6 more cancers than RTX (SIR 0.67); RTX = pop Cancer rate https://t.co/NZnCbMOGQt
  7. Kevzara (Sarilumab) the 2nd IL-6 inhibitor approved for use in RA; priced at $39K, 30% below competition https://t.co/mzIOOhEnMe https://t.co/2U3J2sskum
  8. FDA approves Actemra as1st approved drug to treat Giant Cell Arteritis, based on GiACTA study. https://t.co/73UieZpbn1 https://t.co/HjUzi0H6OL   PI says its to be given with a tapering course of steroids. https://t.co/SCaiX1FDQx
  9. ACR supports FDA draft on interchangeability, naming suffixes & Biosimilar User Fee Act; but not extrapolation- huh? https://t.co/5aKzmwul2N
  10. Survey of 364 UK RA pts shows that giving info on TNFi helps 1/3 and scares 1/3. Many misconceptions about safety https://t.co/lM8gxjjulk
  11. Dr Erkan says secondary THROMBOSIS prevention- Venous-rx warfarin keep INR 2-3; Arterial - warfarin keep INR 2-3 + ASA, or INR 3-4 w/o ASA
  12. Dr Forum Erkan says catastrophic antiphospholipid syndrome should be Rx with anticoagulation, steroids, IVIG w/ plasma exchange (+/- RTX)
  13. Anti-Sclerostin Drug -Romosozumab (EVENITY) Hampered by Heart Problems 
  14. Anti-IL-5 Success in Eosinophilic Granulomatosis with Polyangiitis  
  15. NLRP3 Activation in Still's Disease 
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review - 8 December 2017

Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.

Rheumatology Year in Review

During 2017, the improvements and refinements seen during previous years in the treatment of rheumatoid arthritis have been extending to other conditions ranging from psoriatic arthritis to lupus and for both monoclonal antibodies and oral small molecule medications.

Advances for Biologics

The ACR17 RheumNow Week in Review - 1 December 2017

Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.

ACR Clinical Guidelines Flawed by Low Evidence

JAMA Internal Medicine has reported that recommendations and clinical practice guidelines from the American College of Rheumatology are often based on expert opinion, but lack rigorous (grade A) evidence to support many of their recommendations. 

RheumNow ACR 2017 Awards

The Annual Meeting of the American College of Rheumatology is a gargantuan educational and professional event that is on nearly everyone's radar each year. RheumNow had an expansive effort to cover this meeting and you can review the work of our faculty at ACR17.RheumNow.com.  But we have decided to take this one step further and today we are announcing our 2017 RheumNow ACR Awards.